Daily Cosmetic Research Analysis
Mechanistic dermatology advances identify SLC16A10 as a regulator of keratinocyte arachidonic acid metabolism in psoriasis, suggesting a new therapeutic target. A small randomized trial indicates fractional microneedling radiofrequency augments minoxidil efficacy for female pattern hair loss better than fractional CO2. Translational work with AOPT-LTL IPL shows clinical melasma improvement and links benefit to SCF/c-KIT pathway inhibition.
Summary
Mechanistic dermatology advances identify SLC16A10 as a regulator of keratinocyte arachidonic acid metabolism in psoriasis, suggesting a new therapeutic target. A small randomized trial indicates fractional microneedling radiofrequency augments minoxidil efficacy for female pattern hair loss better than fractional CO2. Translational work with AOPT-LTL IPL shows clinical melasma improvement and links benefit to SCF/c-KIT pathway inhibition.
Research Themes
- Mechanistic targets in inflammatory dermatology
- Energy-based devices for cosmetic dermatology
- Translational bridges from bench to clinic in pigmentation disorders
Selected Articles
1. Role of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes.
Through RNA-seq prioritization and multi-system validation, SLC16A10 emerges as a regulator of keratinocyte arachidonic acid metabolism via thyroid hormone homeostasis, driving psoriatic inflammation. Downregulating SLC16A10 ameliorates disease severity in vitro and in vivo and may influence post-inflammatory hypopigmentation by suppressing melanogenesis.
Impact: Identifies a metabolically anchored, mechanistically validated target (SLC16A10) linking thyroid hormone, lipid metabolism, and psoriatic inflammation, opening therapeutic avenues beyond immune-only strategies.
Clinical Implications: Positions SLC16A10 as a candidate biomarker and therapeutic target for psoriasis, potentially complementing current immune-targeted therapies and informing combination approaches.
Key Findings
- SLC16A10 was identified as a differentially expressed metabolism-related gene with diagnostic and therapeutic potential in psoriasis.
- Functional experiments showed that downregulating SLC16A10 reduced psoriatic hyperinflammation and disease severity in vitro and in vivo.
- Mechanistically, SLC16A10 likely modulates keratinocyte arachidonic acid metabolism via thyroid hormone homeostasis and may also inhibit melanogenesis, contributing to post-inflammatory hypopigmentation.
Methodological Strengths
- Integrated RNA-seq, bioinformatics, and both in vitro and in vivo functional validation.
- Mechanistic linkage across endocrine-metabolic-dermatologic axes (thyroid hormone–lipid metabolism–keratinocyte biology).
Limitations
- Preclinical focus with no randomized human clinical data.
- Generalizability to diverse psoriasis subtypes and human tissue heterogeneity remains to be established.
Future Directions: Validate SLC16A10 as a biomarker in clinical cohorts; develop and test pharmacologic or genetic modulators in psoriasis models; explore synergy with current biologics.
Psoriasis is an inflammatory dermatological condition challenging to treat and prone to recurrence. The pathogenesis of psoriasis is closely associated with metabolic disorders, while therapies targeting the dysregulated metabolism in psoriasis remain limited. Therefore, exploring the pathogenesis of psoriasis and identifying potential metabolic therapeutic targets is imperative. In this study, potential biomarkers for clinically targeted metabolic therapies in patients with psoriasis are aimed to be identified. RNA-sequencing analysis is performed on metabolism-related genes to identify differentially expressed metabolism-related genes. Then, various bioinformatics analyses and comprehensive functional experiments are conducted to verify the roles of the identified genes. A key gene SLC16A10 is identified with significant diagnostic and therapeutic potential for psoriasis. SLC16A10 is likely involved in arachidonic acid metabolism in keratinocytes through regulating thyroid hormone homeostasis, contributing to the development of psoriasis. SLC16A10 represents a promising therapeutic target for guttate psoriasis and can improve the outcomes of existing immune-targeted therapeutic agents. Comprehensive in vitro and in vivo experiments confirm that SLC16A10 downregulation alleviates the severity of psoriasis and hyperinflammation. Moreover, SLC16A10 may induce one of the sequelae of psoriasis, namely post-inflammatory hypopigmentation, by inhibiting melanogenesis. These findings demonstrate the potential of SLC16A10 as a diagnostic biomarker and therapeutic target for psoriasis.
2. Fractional CO2 Versus Radiofrequency as Hair Regrowth Enhancers for Female Androgenic Alopecia: A Randomized Controlled Trial.
In a randomized, two-arm, split-side design with 30 women, both FCO2 and FMRF enhanced outcomes when added to topical 5% minoxidil, but FMRF produced greater gains in trichoscopic hair counts and density. Tolerability was favorable, supporting FMRF as a superior adjuvant to minoxidil for female pattern hair loss.
Impact: Provides comparative RCT evidence favoring fractional microneedling radiofrequency over fractional CO2 as an adjuvant to minoxidil in female pattern hair loss.
Clinical Implications: Supports choosing FMRF over FCO2 when augmenting minoxidil in female pattern hair loss, pending larger, blinded trials to confirm durability and safety.
Key Findings
- All treatment modalities (minoxidil alone, minoxidil+FCO2, minoxidil+FMRF) increased trichoscopic hair counts and density.
- Minoxidil+FMRF produced significantly greater increases in hair counts and density than minoxidil+FCO2 or minoxidil alone.
- Randomization and side-specific treatment allowed within-patient comparison of device effects.
Methodological Strengths
- Randomized allocation with split-side scalp treatment enabling intra-individual control.
- Objective trichoscopic endpoints (hair counts and density).
Limitations
- Small sample size (n=30) with short-term assessment and unclear blinding.
- No long-term durability or safety outcomes reported.
Future Directions: Conduct larger, blinded RCTs with standardized protocols, longer follow-up, and patient-reported outcomes to confirm superiority and safety of FMRF.
BACKGROUND: Androgenic alopecia (AGA) is a cosmetically disfiguring condition, which accounts for most cases of diffuse hair loss among females, negatively impacting their quality of life. Combining Fractional CO2 (FCO2) or Fractional Microneedling Radiofrequency (FMRF) with topical minoxidil 5% could achieve a better clinical outcome. OBJECTIVE: To compare efficacy and safety of FCO2 and FMRF, combined with minoxidil, for the treatment of female AGA. METHODS: Thirty patients with female AGA were randomly assigned to 2 groups (simple computerized randomization). Group A patients received FCO2 to 1 randomly selected side of the scalp, and Group B patients received FMRF to 1 randomly selected side of the scalp (picking masked labeled cards). Patients received minoxidil 5%. RESULTS: Significant increase in trichoscopic hair counts and density was found after treatment with each modality whether minoxidil 5% alone, minoxidil combined with FCO2, or minoxidil combined with FMRF. A significantly greater increase in trichoscopic hair counts and density followed the treatment with minoxidil + FMRF, compared to either minoxidil + FCO2 or minoxidil alone. CONCLUSION: It can be proposed that combining FMRF with minoxidil for the treatment of female AGA could be associated with higher efficacy and tolerability, compared to the other treatment modalities.
3. Efficacy of Intense Pulsed Light AOPT-LTL Technique in the Treatment of Melasma: An In Vivo and Clinical Study.
AOPT-LTL IPL reduced pigmentation, inflammation, angiogenesis, mast cell infiltration, and collagen degradation in a guinea pig melasma model, concomitant with suppression of SCF/c-KIT signaling. In 20 patients, three monthly sessions lowered melanin and erythema with improved mMASI and EI scores.
Impact: Links a specific IPL delivery mode to multi-pathway biological effects and clinical improvement in melasma, providing mechanistic rationale (SCF/c-KIT inhibition) for protocol optimization.
Clinical Implications: Supports low-energy triple-pulse long-width IPL as a viable option for melasma with concurrent anti-inflammatory and anti-angiogenic effects; parameterization may reduce rebound and adverse effects.
Key Findings
- In vivo AOPT-LTL IPL decreased pigmentation and downregulated melanogenic enzymes, inflammatory mediators, and pro-angiogenic factors.
- AOPT-LTL reduced mast cell infiltration and suppressed SCF/c-KIT signaling, a pathway linked to mast cell activation.
- In 20 patients, three monthly AOPT-LTL sessions reduced melanin content and erythema, improving mMASI and EI scores.
Methodological Strengths
- Translational design integrating mechanistic in vivo work with clinical patient outcomes.
- Multi-omic readouts (qRT-PCR, immunofluorescence/Western blot) to map pathway effects.
Limitations
- Clinical arm is an uncontrolled small case series (n=20) with short follow-up.
- Generalizability across Fitzpatrick skin types and relapse prevention not established.
Future Directions: Randomized, controlled trials comparing AOPT-LTL with other IPL parameters and lasers; biomarker-guided personalization targeting SCF/c-KIT and angiogenesis.
PURPOSE: To evaluate the efficacy and underlying mechanism of advanced optimal pulse technology intense pulsed light (AOPT) in low-energy triple-pulse long-width mode (AOPT-LTL) for melasma treatment. METHODS: An in vivo guinea pig model of melasma was established through progesterone injection and ultraviolet B radiation. Three sessions of AOPT-LTL treatment were performed weekly. The mRNA levels of key melanogenic enzymes, inflammatory factors, pro-angiogenic cytokines, and collagenolytic proteases were detected by qRT-PCR. Protein levels of stem cell factor (SCF) and mast cell growth factor receptor (c-KIT) were detected by immunofluorescence staining and Western blotting. Twenty melasma patients were treated with three sessions of AOPT-LTL treatment monthly, evaluated by the Modified Melasma Area and Severity Index (mMASI) and Erythema Index (EI). RESULTS: In guinea pigs with melasma, AOPT-LTL treatment effectively mitigated pigmentation and suppressed the expression of key genes involved in melanin production. There was a reduction in mast cell infiltration, decreased expression of inflammatory factors and pro-angiogenic factors, inhibition of angiogenesis, and alleviation of skin photoaging. Furthermore, AOPT-LTL also diminished the expression level of the SCF/c-KIT ligand/receptor pathway, which is closely associated with mast cell proliferation and activation. Consistently, three sessions of AOPT-LTL treatment effectively reduced skin melanin content, erythema severity, as well as the mMASI and EI scores in melasma patients. CONCLUSIONS: AOPT-LTL treatment significantly enhances the improvement of melasma by diminishing melanogenesis, inflammation, angiogenesis, mast cell infiltration, and collagen degeneration, potentially through the inhibition of the SCF/c-KIT ligand/receptor pathway.